Pei‐Pei Kung

Pfizer (United States) — United States

Computer Science · Physical Sciences

20h-index2.2kcitations102works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(24), Microtubule and mitosis dynamics(20), Biological Research and Disease Studies(16), Glutathione Transferases and Polymorphisms(14), Heat shock proteins research(13)

Publications102 total

Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer
Molecular Cancer Therapeutics·2025
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
Cancer Research·2025
Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D)
Bioorganic & Medicinal Chemistry Letters·2023· 1 citedOpen Access
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Cell chemical biology·2023· 59 citedOpen Access
Identification of small-molecule protein–protein interaction inhibitors for NKG2D
Proceedings of the National Academy of Sciences·2023· 11 citedOpen Access
Supplementary Table 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 1 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 2 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 1 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Materials and Methods from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Materials and Methods from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 1 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Data from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Data from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 2 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 2 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Table 2 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure 4 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Shinji Yamazaki(17), Buwen Huang(16), Karen A. Maegley(13), Pramod P. Mehta(12), Patrick Bingham(10), Min-Jean Yin(10), K.S. Gajiwala(8), Scott C. Sutton(8), Luke R. Zehnder(8), Michael R. Gehring(7), Connie Fan(6), Hovhannes J. Gukasyan(6), Susan E. Kephart(6), Pamela Whalen(6), Jerry Meng(5), Robert S. Kania(5), Cody Krivacic(5), Shikhar Sharma(5), Sean Uryu(5), Martin Wythes(5)